The management of coumarin-induced over-anticoagulation Annotation.
Makris
M
M
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK. m.makris@sheffield.ac.uk
Watson
H G
HG
D000074:Acenocoumarol / Q000009:adverse effects; D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006207:Half-Life; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D019934:International Normalized Ratio; D018579:Patient Selection; D010644:Phenprocoumon / Q000009:adverse effects; D012306:Risk; D014812:Vitamin K / Q000627:therapeutic use; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
D000925:Anticoagulants; D014812:Vitamin K; D014859:Warfarin; D000074:Acenocoumarol; D010644:Phenprocoumon